Pegcetacoplan (Aspaveli®) – Paroxysmal nocturnal haemoglobinuria (PNH), pre-treated patients

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Pegcetacoplan
Brand name Aspaveli®
Pharm. company Swedish Orphan Biovitrum GmbH
G-BA procedure ID 2022-04-01-D-770
Therapeutic area Hematopoietic diseases ORPHAN
Reason for procedure Initial assessment

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Aspaveli is used for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who remain anaemic for at least 3 months after treatment with a C5 inhibitor.

Subpopulation Indication Comparator
Adults with paroxysmal nocturnal haemoglobinuria (PNH) who remain anaemic after treatment with a C5 inhibitor which are still anaemic for at least 3 months after treatment Not applicabl

9. Associated procedures



<< List of all resolutions